MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1212/wnl.0000000000002745

Медицинская библиотека · Neurology · 2016

Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.

Buttmann Mathias, Seuffert Linda, Mäder Uwe, Toyka Klaus V

Сравнительное исследованиеСтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

To assess the therapy-related risk of malignancies in mitoxantrone-treated patients with multiple sclerosis.

METHODS

This retrospective observational cohort study included all mitoxantrone-treated patients with multiple sclerosis seen at our department between 1994 and 2007. We collected follow-up information on medically confirmed malignancies, life status, and cause of death, as of 2010. Malignancy rates were compared to the German national cancer registry matched for sex, age, and year of occurrence.

RESULTS

Follow-up was completed in 676 of 677 identified patients. Median follow-up time was 8.7 years (interquartile range 6.8-11.2), corresponding to 6,220 person-years. Median cumulative mitoxantrone dose was 79.0 mg/m(2) (interquartile range 50.8-102.4). Thirty-seven patients (5.5%) were diagnosed with a malignancy after mitoxantrone initiation, revealing a standardized incidence ratio of 1.50 (95% confidence interval [CI] 1.05-2.08). Entities included breast cancer (n = 9), colorectal cancer (n = 7), acute myeloid leukemia (n = 4, 0.6%), and others (each entity n = 1 or 2). The standardized incidence ratio of colorectal cancer was 2.98 (95% CI 1.20-6.14) and of acute myeloid leukemia 10.44 (95% CI 3.39-24.36). It was not increased for other entities including breast cancer. Multivariate Cox regression identified higher age at treatment initiation but neither cumulative mitoxantrone dose (>75 vs ≤75 mg/m(2)) nor treatment with other immunosuppressive drugs or sex as a risk factor. Fifty-five patients had died, among them 12 of a malignancy and 43 reportedly of other causes.

CONCLUSIONS

While the overall incidence of malignancies was only mildly increased, the risk of leukemia and colorectal cancer was heightened. If confirmed, posttherapy colonoscopy could become advisable.

Для цитирования: Buttmann Mathias, Seuffert Linda, Mäder Uwe, Toyka Klaus V. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.. Neurology. 2016. DOI: 10.1212/wnl.0000000000002745.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.